Review on Databases and Bioinformatic Approaches on Pharmacogenomics of Adverse Drug Reactions

References

• Wheatley LM, Plaut M, Schwaninger JM, et al. Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy. J Allergy Clin Immunol. 2015;136(2):262–71.e2. doi:10.1016/j.jaci.2015.05.027
   Web of Science ®Google Scholar
• Uetrecht J. Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol. 2007;47(1):513–539. doi:10.1146/annurev.pharmtox.47.120505.105150
   PubMed Web of Science ®Google Scholar
• Hunziker T, Künzi U-P, Braunschweig S, et al. Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey. Allergy. 1997;52(4):388–393. doi:10.1111/j.1398-9995.1997.tb01017.x
   PubMed Web of Science ®Google Scholar
• Valeyrie-Allanore L, Sassolas B, Roujeau JC. Drug-induced skin, nail and hair disorders. Drug Saf. 2007;30(11):1011–1030. doi:10.2165/00002018-200730110-00003
   PubMed Web of Science ®Google Scholar
• Sidenius S,PCT,P, Dam M. Lamotrigine-induced rash–worth a rechallenge. Acta Neurol Scand. 2005;111(3):191–194. doi:10.1111/j.1600-0404.2005.00381.x
   Web of Science ®Google Scholar
• Vonakis BM, Saini SS. New concepts in chronic urticaria. Curr Opin Immunol. 2008;20(6):709–716. doi:10.1016/j.coi.2008.09.005
   PubMed Web of Science ®Google Scholar
• Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Acad Dermatol. 2007;56(2):181–200. doi:10.1016/j.jaad.2006.04.048
   PubMed Web of Science ®Google Scholar
• Downey A, Jackson C, Harun N, et al. Toxic epidermal necrolysis: review of pathogenesis and management. J Am Acad Dermatol. 2012;66(6):995–1003. doi:10.1016/j.jaad.2011.09.029
   PubMed Web of Science ®Google Scholar
• Tang YH, Mockenhaupt M, Henry A, et al. Poor relevance of a lymphocyte proliferation assay in lamotrigine-induced Stevens-Johnson syndrome or toxic epidermal necrolysis. Clin Exp Allergy. 2012;42(2):248–254. doi:10.1111/j.1365-2222.2011.03875.x
   Web of Science ®Google Scholar
• Wei C-Y, Chung W-H, Huang H-W, et al. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J Allergy Clin Immunol. 2012;129(6):1562–9e5. doi:10.1016/j.jaci.2011.12.990
   PubMed Web of Science ®Google Scholar
• Bjornsson E. Review article: drug-induced liver injury in clinical practice. Aliment Pharmacol Ther. 2010;32(1):3–13. doi:10.1111/j.1365-2036.2010.04320.x
   PubMed Web of Science ®Google Scholar
• Clay KD, et al. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med. 2006;144(6):415–420. doi:10.7326/0003-4819-144-6-200503210-00121
   Web of Science ®Google Scholar
• Orman ES, Conjeevaram HS, Vuppalanchi R, et al. Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol. 2011;9(6):517–523e3. doi:10.1016/j.cgh.2011.02.019
   PubMed Web of Science ®Google Scholar
• Tesfa D, Palmblad J. Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms. Expert Rev Hematol. 2011;4(6):619–625. doi:10.1586/ehm.11.62
   PubMed Web of Science ®Google Scholar
• Tesfa D, Keisu M, Palmblad J. Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management. Am J Hematol. 2009;84(7):428–434. doi:10.1002/ajh.21433
   PubMed Web of Science ®Google Scholar
• Aster RH, Curtis BR, McFarland JG, et al. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management. J Thromb Haemost. 2009;7(6):911–918. doi:10.1111/j.1538-7836.2009.03360.x
   PubMed Web of Science ®Google Scholar
• Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. N Engl J Med. 2003;348(16):1556–1564. doi:10.1056/NEJMsa020703
   PubMed Web of Science ®Google Scholar
• Gomes ER, Demoly P. Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol. 2005;5(4):309–316. doi:10.1097/01.all.0000173785.81024.33
   PubMed Web of Science ®Google Scholar
• Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200–1205. doi:10.1001/jama.279.15.1200
   PubMed Web of Science ®Google Scholar
• Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255–1259. doi:10.1016/S0140-6736(00)02799-9
   PubMed Web of Science ®Google Scholar
• Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: report of the nomenclature review committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113(5):832–836. doi:10.1016/j.jaci.2003.12.591
   PubMed Web of Science ®Google Scholar
• FDA. Table of Pharmacogenomic Biomarkers in Drug Labeling; 2019.
   Google Scholar
• Kaniwa N, Saito Y, Aihara M, et al. HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia. 2010;51(12):2461–2465. doi:10.1111/j.1528-1167.2010.02766.x
   PubMed Web of Science ®Google Scholar
• Kim S-H, Lee KW, Song W-J, et al. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy Res. 2011;97(1–2):190–197. doi:10.1016/j.eplepsyres.2011.08.010
   PubMed Web of Science ®Google Scholar
• Tassaneeyakul W, Tiamkao S, Jantararoungtong T, et al. Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia. 2010;51(5):926–930. doi:10.1111/j.1528-1167.2010.02533.x
   PubMed Web of Science ®Google Scholar
• Hsiao YH, Hui RC-Y, Wu T, et al. Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations. J Dermatol Sci. 2014;73(2):101–109. doi:10.1016/j.jdermsci.2013.10.003
   Web of Science ®Google Scholar
• Yuliwulandari R, Kristin E, Prayuni K, et al. Association of the HLA-B alleles with carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in the Javanese and Sundanese population of Indonesia: the important role of the HLA-B75 serotype. Pharmacogenomics. 2017;18(18):1643–1648. doi:10.2217/pgs-2017-0103
   PubMed Web of Science ®Google Scholar
• Chen P, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med. 2011;364(12):1126–1133. doi:10.1056/NEJMoa1009717
   PubMed Web of Science ®Google Scholar
• Manglani MV, Gabhale YR, Lala MM, et al. HLA- B*5701 Allele in HIV-infected indian children and its association with abacavir hypersensitivity. Indian Pediatr. 2018;55(2):140–141. doi:10.1007/s13312-018-1248-x
   Web of Science ®Google Scholar
• Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359(9308):727–732. doi:10.1016/S0140-6736(02)07873-X
   PubMed Web of Science ®Google Scholar
• Agbaji OO, Akanbi M, Otoh I, et al. Absence of human leukocyte antigen-B*57:01 amongst patients on antiretroviral therapy in Nigeria: implications for use of abacavir. Niger Postgrad Med J. 2019;26(4):195–198. doi:10.4103/npmj.npmj_75_19
   Google Scholar
• Small CB, Margolis DA, Shaefer MS, et al. HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects. BMC Infect Dis. 2017;17(1):256. doi:10.1186/s12879-017-2331-y
   PubMed Web of Science ®Google Scholar
• Baniasadi S, et al. Prevalence of HLA-B*5701 and its relationship with abacavir hypersensitivity reaction in Iranian HIV-infected patients. Tanaffos. 2016;15(1):48–52.
   PubMedGoogle Scholar
• Martin AM, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci U S A. 2004;101(12):4180–4185.
   PubMed Web of Science ®Google Scholar
• Sun HY, Numanagić I, Malikić S, et al. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan. J Antimicrob Chemother. 2007;60(3):599–604. doi:10.1093/jac/dkm243
   Web of Science ®Google Scholar
• Arrieta-Bolanos E, Madrigal JA, Marsh SGE, et al. The frequency of HLA-B(*)57:01 and the risk of abacavir hypersensitivity reactions in the majority population of Costa Rica. Hum Immunol. 2014;75(11):1092–1096. doi:10.1016/j.humimm.2014.09.011
   Web of Science ®Google Scholar
• Hughes AR, Mosteller M, Bansal AT, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics. 2004;5(2):203–211. doi:10.1517/phgs.5.2.203.27481
   Web of Science ®Google Scholar
• Nakkam N, et al. HLA pharmacogenetic markers of drug hypersensitivity in a Thai Population. Front Genet. 2018;9:277. doi:10.3389/fgene.2018.00277
   PubMed Web of Science ®Google Scholar
• Jaruthamsophon K, Tipmanee V, Sangiemchoey A, et al. HLA-B*15:21 and carbamazepine-induced Stevens-Johnson syndrome: pooled-data and in silico analysis. Sci Rep. 2017;7(1):45553. doi:10.1038/srep45553
   PubMed Web of Science ®Google Scholar
• Cargnin S, Jommi C, Canonico PL, et al. Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review. Pharmacogenomics. 2014;15(7):963–976. doi:10.2217/pgs.14.52
   PubMed Web of Science ®Google Scholar
• Ang HX, Chan SL, Sani LL, et al. Pharmacogenomics in Asia: a systematic review on current trends and novel discoveries. Pharmacogenomics. 2017;18(9):891–910. doi:10.2217/pgs-2017-0009
   PubMed Web of Science ®Google Scholar
• Ayuso P, Plaza-Serón MDC, Blanca-López N, et al. Genetic variants in arachidonic acid pathway genes associated with NSAID-exacerbated respiratory disease. Pharmacogenomics. 2015;16(8):825–839. doi:10.2217/pgs.15.43
   Web of Science ®Google Scholar
• de Oliveira Rodrigues R, Helena Barem Rabenhorst S, Germano de Carvalho P, et al. Association of IL10, IL4, IFNG, and CTLA4 Gene polymorphisms with efavirenz hypersensitivity reaction in patients infected with human immunodeficiency virus. Jpn J Infect Dis. 2017;70(4):430–436. doi:10.7883/yoken.JJID.2016.075
   PubMed Web of Science ®Google Scholar
• Smith RP, Eckalbar WL, Morrissey KM, et al. Genome-wide discovery of drug-dependent human liver regulatory elements. PLoS Genet. 2014;10(10):e1004648. doi:10.1371/journal.pgen.1004648
   Web of Science ®Google Scholar
• Wadelius M. Point: use of pharmacogenetics in guiding treatment with warfarin. Clin Chem. 2009;55(4):709–711. doi:10.1373/clinchem.2008.115964
   Web of Science ®Google Scholar
• Nguyen DV, Vidal C, Chu HC, et al. Developing pharmacogenetic screening methods for an emergent country: vietnam. World Allergy Organ J. 2019;12(5):100037. doi:10.1016/j.waojou.2019.100037
   Web of Science ®Google Scholar
• Pan C-W, Yu C-H, Liao D-L. Carbamazepine-induced hypersensitivity syndrome in chronic schizophrenia. Gen Hosp Psychiatry. 2013;35(5):575 e9–10. doi:10.1016/j.genhosppsych.2012.08.004
   Web of Science ®Google Scholar
• Dello Russo C, Lisi L, Fabbiani M, et al. Detection of HLA-B*57:01 by real-time PCR: implementation into routine clinical practice and additional validation data. Pharmacogenomics. 2014;15(3):319–327. doi:10.2217/pgs.13.242
   Web of Science ®Google Scholar
• Moragas M, Belloso WH, Baquedano MS, et al. Prevalence of HLA-B*57:01 allele in Argentinean HIV-1 infected patients. Tissue Antigens. 2015;86(1):28–31. doi:10.1111/tan.12575
   Google Scholar
• Dello Russo C, Lisi L, Lofaro A, et al. Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR. Pharmacogenomics. 2011;12(4):567–576. doi:10.2217/pgs.10.208
   Web of Science ®Google Scholar
• Aggarwal R, Sharma M, Modi M, et al. HLA-B * 1502 is associated with carbamazepine induced Stevens-Johnson syndrome in North Indian population. Hum Immunol. 2014;75(11):1120–1122. doi:10.1016/j.humimm.2014.09.022
   Web of Science ®Google Scholar
• Nguyen DV, Chu HC, Nguyen DV, et al. HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese. Asia Pac Allergy. 2015;5(2):68–77. doi:10.5415/apallergy.2015.5.2.68
   PubMed Web of Science ®Google Scholar
• Mushiroda T, et al. Association of HLA-A*31:01 screening with the incidence of carbamazepine-induced cutaneous adverse reactions in a Japanese population. JAMA Neurol. 2018;75(7):842–849.
   PubMed Web of Science ®Google Scholar
• Nguyen DV, Vidal C, Chi HC, et al. A novel multiplex polymerase chain reaction assay for detection of both HLA-A*31:01/HLA-B*15:02 alleles, which confer susceptibility to carbamazepine-induced severe cutaneous adverse reactions. HLA. 2017;90(6):335–342. doi:10.1111/tan.13143
   Web of Science ®Google Scholar
• Ciccacci C, et al. Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study. Eur J Clin Pharmacol. 2013;69(11):1909–1916. doi:10.1007/s00228-013-1549-x
   PubMed Web of Science ®Google Scholar
• Ciccacci C, Rufini S, Mancinelli S, et al. A pharmacogenetics study in Mozambican patients treated with nevirapine: full resequencing of TRAF3IP2 gene shows a novel association with SJS/TEN susceptibility. Int J Mol Sci. 2015;16(3):5830–5838. doi:10.3390/ijms16035830
   Web of Science ®Google Scholar
• Carr DF, Chaponda M, Cornejo Castro EM, et al. CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations. J Antimicrob Chemother. 2014;69(12):3329–3334. doi:10.1093/jac/dku315
   Web of Science ®Google Scholar
• Cheung Y-K, Cheng S-H, Chan EJM, et al. HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia. 2013;54(7):1307–1314. doi:10.1111/epi.12217
   PubMed Web of Science ®Google Scholar
• Chang -C-C, Ng -C-C, Too C-L, et al. Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population. Pharmacogenomics J. 2017;17(2):170–173. doi:10.1038/tpj.2016.10
   PubMed Web of Science ®Google Scholar
• Tassaneeyakul W, Prabmeechai N, Sukasem C, et al. Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population. Pharmacogenet Genomics. 2016;26(5):225–234. doi:10.1097/FPC.0000000000000211
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, Alfirevic A, Vilar J, et al. Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity. Pharmacogenetics. 2000;10(8):705–713. doi:10.1097/00008571-200011000-00005
   PubMedGoogle Scholar
• Scharfe CPI, Tremmel R, Schwab M, et al. Genetic variation in human drug-related genes. Genome Med. 2017;9(1):117. doi:10.1186/s13073-017-0502-5
   PubMed Web of Science ®Google Scholar
• Low S-K, Takahashi A, Mushiroda T, et al. Genome-wide association study: a useful tool to identify common genetic variants associated with drug toxicity and efficacy in cancer pharmacogenomics. Clin Cancer Res. 2014;20(10):2541–2552. doi:10.1158/1078-0432.CCR-13-2755
   Web of Science ®Google Scholar
• Buniello A, et al., The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res, 2019. 47(D1): D1005–D1012.
   Google Scholar
• Klein RJ. Power analysis for genome-wide association studies. BMC Genet. 2007;8(1):58. doi:10.1186/1471-2156-8-58
   Web of Science ®Google Scholar
• Zondervan KT, Cardon LR. Designing candidate gene and genome-wide case-control association studies. Nat Protoc. 2007;2(10):2492–2501. doi:10.1038/nprot.2007.366
   PubMed Web of Science ®Google Scholar
• Spencer CC, et al. Designing genome-wide association studies: sample size, power, imputation, and the choice of genotyping chip. PLoS Genet. 2009;5(5):e1000477.
   PubMed Web of Science ®Google Scholar
• Wu Z, Zhao H, Walsh B. Statistical power of model selection strategies for genome-wide association studies. PLoS Genet. 2009;5(7):e1000582. doi:10.1371/journal.pgen.1000582
   PubMed Web of Science ®Google Scholar
• Park J-H, Wacholder S, Gail MH, et al. Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat Genet. 2010;42(7):570–575. doi:10.1038/ng.610
   PubMed Web of Science ®Google Scholar
• Hong EP, Park JW. Sample size and statistical power calculation in genetic association studies. Genomics Inform. 2012;10(2):117–122. doi:10.5808/GI.2012.10.2.117
   PubMedGoogle Scholar
• Wu R, Tong C, Wang Z, et al. A conceptual framework for pharmacodynamic genome-wide association studies in pharmacogenomics. Drug Discov Today. 2011;16(19–20):884–890. doi:10.1016/j.drudis.2011.09.001
   Web of Science ®Google Scholar
• Hayes B. Overview of statistical methods for Genome-Wide Association Studies (GWAS). Methods Mol Biol. 2013;1019:149–169.
   Google Scholar
• Carr DF, Bourgeois S, Chaponda M, et al. Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population. J Antimicrob Chemother. 2017;72(4):1152–1162. doi:10.1093/jac/dkw545
   PubMed Web of Science ®Google Scholar
• Chantarangsu S, Mushiroda T, Mahasirimongkol S, et al. Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash. Clin Infect Dis. 2011;53(4):341–348. doi:10.1093/cid/cir403
   PubMed Web of Science ®Google Scholar
• Reinhart JM, Motsinger-Reif A, Dickey A, et al. Genome-wide association study in immunocompetent patients with delayed hypersensitivity to sulfonamide antimicrobials. PLoS One. 2016;11(6):e0156000. doi:10.1371/journal.pone.0156000
   Web of Science ®Google Scholar
• Zhang F-R, Liu H, Irwanto A, et al. HLA-B*13:01 and the Dapsone Hypersensitivity Syndrome. N Engl J Med. 2013;369(17):1620–1628. doi:10.1056/NEJMoa1213096
   PubMed Web of Science ®Google Scholar
• Gueant J-L, Romano A, Cornejo-Garcia J-A, et al. HLA-DRA variants predict penicillin allergy in genome-wide fine-mapping genotyping. J Allergy Clin Immunol. 2015;135(1):253–259. doi:10.1016/j.jaci.2014.07.047
   Web of Science ®Google Scholar
• Cornejo-Garcia JA, Liou L-B, Blanca-López N, et al. Genome-wide association study in NSAID-induced acute urticaria/angioedema in Spanish and Han Chinese populations. Pharmacogenomics. 2013;14(15):1857–1869. doi:10.2217/pgs.13.166
   Web of Science ®Google Scholar
• Park BL, Kim T-H, Kim J-H, et al. Genome-wide association study of aspirin-exacerbated respiratory disease in a Korean population. Hum Genet. 2013;132(3):313–321. doi:10.1007/s00439-012-1247-2
   PubMed Web of Science ®Google Scholar
• Kim J-H, Park B-L, Cheong HS, et al. Genome-wide and follow-up studies identify CEP68 gene variants associated with risk of aspirin-intolerant asthma. PLoS One. 2010;5(11):e13818. doi:10.1371/journal.pone.0013818
   Web of Science ®Google Scholar
• Ueta M, Sotozono C, Nakano M, et al. Association between prostaglandin E receptor 3 polymorphisms and Stevens-Johnson syndrome identified by means of a genome-wide association study. J Allergy Clin Immunol. 2010;126(6):1218–25e10. doi:10.1016/j.jaci.2010.08.007
   PubMed Web of Science ®Google Scholar
• McCormack M, Urban TJ, Shianna KV, et al. Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions. Pharmacogenomics. 2012;13(4):399–405. doi:10.2217/pgs.11.165
   PubMed Web of Science ®Google Scholar
• Su SC, Chen C-B, Chang W-C, et al. HLA Alleles and CYP2C9*3 as predictors of phenytoin hypersensitivity in East Asians. Clin Pharmacol Ther. 2019;105(2):476–485. doi:10.1002/cpt.1190
   PubMed Web of Science ®Google Scholar
• Jang HW, Kim SW, Cho Y-J, et al. GWAS identifies two susceptibility loci for lamotrigine-induced skin rash in patients with epilepsy. Epilepsy Res. 2015;115:88–94. doi:10.1016/j.eplepsyres.2015.05.014
   Web of Science ®Google Scholar
• Ozeki T, Mushiroda T, Yowang A, et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet. 2011;20(5):1034–1041. doi:10.1093/hmg/ddq537
   PubMed Web of Science ®Google Scholar
• McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011;364(12):1134–1143. doi:10.1056/NEJMoa1013297
   PubMed Web of Science ®Google Scholar
• Shen Y, Nicoletti P, Floratos A, et al. Genome-wide association study of serious blistering skin rash caused by drugs. Pharmacogenomics J. 2012;12(2):96–104. doi:10.1038/tpj.2010.84
   Web of Science ®Google Scholar
• Tohkin M, et al. A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Pharmacogenomics J. 2013;13(1):60–69. doi:10.1038/tpj.2011.41
   PubMed Web of Science ®Google Scholar
• Fernandez CA, Smith C, Yang W, et al. Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. Blood. 2015;126(1):69–75. doi:10.1182/blood-2015-02-628800
   Web of Science ®Google Scholar
• Nishino J, Ochi H, Kochi Y, et al. Sample size for successful genome-wide association study of major depressive disorder. Front Genet. 2018;9:227. doi:10.3389/fgene.2018.00227
   Web of Science ®Google Scholar
• Lee SH, Clark S, van der Werf JHJ. Estimation of genomic prediction accuracy from reference populations with varying degrees of relationship. PLoS One. 2017;12(12):e0189775. doi:10.1371/journal.pone.0189775
   Web of Science ®Google Scholar
• International HapMap C. A haplotype map of the human genome. Nature. 2005;437(7063):1299–1320.
   PubMed Web of Science ®Google Scholar
• Fadista J, Manning AK, Florez JC, et al. The (in)famous GWAS P-value threshold revisited and updated for low-frequency variants. Eur J Hum Genet. 2016;24(8):1202–1205. doi:10.1038/ejhg.2015.269
   PubMed Web of Science ®Google Scholar
• Klaewsongkram J, Sukasem C, Thantiworasit P, et al. Analysis of HLA-B allelic variation and IFN-gamma ELISpot responses in patients with severe cutaneous adverse reactions associated with drugs. J Allergy Clin Immunol Pract. 2019;7(1):219–227e4. doi:10.1016/j.jaip.2018.05.004
   Web of Science ®Google Scholar
• Watanabe H, Watanabe Y, Tashiro Y, et al. A docking model of dapsone bound to HLA-B*13:01 explains the risk of dapsone hypersensitivity syndrome. J Dermatol Sci. 2017;88(3):320–329. doi:10.1016/j.jdermsci.2017.08.007
   PubMed Web of Science ®Google Scholar
• Schäfer D, Brumen M, Dobovišek A, et al. Dynamic model of eicosanoid production with special reference to non-steroidal anti-inflammatory drug-triggered hypersensitivity. IET Systems Biology. 2015;9(5):204–215. doi:10.1049/iet-syb.2014.0037
   Web of Science ®Google Scholar
• Ammar R, Paton TA, Torti D, et al. Long read nanopore sequencing for detection of HLA and CYP2D6 variants and haplotypes [version 2; peer review: 2 approved]. F1000Research. 2015;4(17):17. doi:10.12688/f1000research.6037.2
   Google Scholar
• Laver TW, et al. Pitfalls of haplotype phasing from amplicon-based long-read sequencing. Sci Rep. 2016;6:21746. doi:10.1038/srep21746
   PubMed Web of Science ®Google Scholar
• Ambardar S, Gowda M. High-resolution full-length HLA typing method using third generation (Pac-Bio SMRT) sequencing technology. Methods Mol Biol. 2018;1802:135–153.
   Google Scholar
• Suzuki S, Ranade S, Osaki K, et al. Reference Grade Characterization of Polymorphisms in Full-Length HLA Class I and II genes with short-read sequencing on the ION PGM system and long-reads generated by single molecule, real-time sequencing on the pacbio platform. Front Immunol. 2018;9:2294. doi:10.3389/fimmu.2018.02294
   Web of Science ®Google Scholar
• Buermans HPJ, Vossen RHAM, Anvar SY, et al. Flexible and scalable full-length CYP2D6 long amplicon PacBio sequencing. Hum Mutat. 2017;38(3):310–316. doi:10.1002/humu.23166
   Web of Science ®Google Scholar
• Hripcsak G, Ryan PB, Duke JD, et al. Characterizing treatment pathways at scale using the OHDSI network. Proc Natl Acad Sci. 2016;113(27):7329–7336. doi:10.1073/pnas.1510502113
   Web of Science ®Google Scholar
• Dey S, Luo H, Fokoue A, et al. Predicting adverse drug reactions through interpretable deep learning framework. BMC Bioinform. 2018;19(S21):476. doi:10.1186/s12859-018-2544-0
   Web of Science ®Google Scholar
• Poudel DR, Acharya P, Ghimire S, et al. Burden of hospitalizations related to adverse drug events in the USA: a retrospective analysis from large inpatient database. Pharmacoepidemiol Drug Saf. 2017;26(6):635–641. doi:10.1002/pds.4184
   PubMed Web of Science ®Google Scholar
• Barbarino JM, Whirl-Carrillo M, Altman RB, et al. PharmGKB: a worldwide resource for pharmacogenomic information. WIREs Syst Biol Med. 2018;10(4):e1417. doi:10.1002/wsbm.1417
   Google Scholar
• Davis AP, Grondin CJ, Johnson RJ, et al. The comparative toxicogenomics database: update 2019. Nucleic Acids Res. 2019;47(D1):D948–D954. doi:10.1093/nar/gky868
   PubMed Web of Science ®Google Scholar
• Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30. doi:10.1093/nar/28.1.27
   PubMed Web of Science ®Google Scholar
• Hecker N, et al. SuperTarget goes quantitative: update on drug-target interactions. Nucleic Acids Res. 2012;40(Database issue):D1113–D1117.
   PubMed Web of Science ®Google Scholar
• Ghattaoraya GS, et al. A web resource for mining HLA associations with adverse drug reactions: HLA-ADR. Database. 2016;2016.
   Google Scholar
• Cai M-C, Xu Q, Pan Y-J, et al. ADReCS: an ontology database for aiding standardization and hierarchical classification of adverse drug reaction terms. Nucleic Acids Res. 2015;43(Database issue):D907–D913. doi:10.1093/nar/gku1066
   Web of Science ®Google Scholar
• Ji ZL, Han LY, Yap CW, et al. Drug ADVERSE Reaction Target Database (DART): proteins related to adverse drug reactions. Drug Safety. 2003;26(10):685–690. doi:10.2165/00002018-200326100-00002
   Web of Science ®Google Scholar
• Van der Auwera GA, et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr Protoc Bioinformatics. 2013;43(1110):11.10.1–11.10.33.
   Google Scholar
• Li H, Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv preprint arXiv:1303.3997, 2013.
   Google Scholar
• Poplin R, Chang P-C, Alexander D, et al. A universal SNP and small-indel variant caller using deep neural networks. Nat Biotechnol. 2018;36(10):983–987. doi:10.1038/nbt.4235
   PubMed Web of Science ®Google Scholar
• Twist GP, Gaedigk A, Miller NA, et al. Erratum: constellation: a tool for rapid, automated phenotype assignment of a highly polymorphic pharmacogene, CYP2D6, from whole-genome sequences. Npj Genomic Med. 2017;2(1):16039. doi:10.1038/npjgenmed.2016.39
   Web of Science ®Google Scholar
• Chen X, et al., Accurate CYP2D6 genotyping using whole genome sequencing data. bioRxiv, 2020: p. 2020.
   Google Scholar
• Numanagić I, Malikić S, Ford M, et al. Allelic decomposition and exact genotyping of highly polymorphic and structurally variant genes. Nat Commun. 2018;9(1):828. doi:10.1038/s41467-018-03273-1
   Web of Science ®Google Scholar
• Lee S-B, Wheeler MM, Thummel KE, et al. Calling star alleles with stargazer in 28 pharmacogenes with whole genome sequences. Clin Pharmacol Ther. 2019;106(6):1328–1337. doi:10.1002/cpt.1552
   Web of Science ®Google Scholar
• Boegel S, Löwer M, Schäfer M, et al. HLA typing from RNA-Seq sequence reads. Genome Med. 2012;4(12):102. doi:10.1186/gm403
   PubMed Web of Science ®Google Scholar
• Szolek A, Schubert B, Mohr C, et al. OptiType: precision HLA typing from next-generation sequencing data. Bioinformatics (Oxford, England). 2014;30(23):3310–3316. doi:10.1093/bioinformatics/btu548
   PubMed Web of Science ®Google Scholar
• Kawaguchi S, Higasa K, Shimizu M, et al. HLA-HD: an accurate HLA typing algorithm for next-generation sequencing data. Hum Mutat. 2017;38(7):788–797. doi:10.1002/humu.23230
   PubMed Web of Science ®Google Scholar
• Lee H, Kingsford C. Kourami: graph-guided assembly for novel human leukocyte antigen allele discovery. Genome Biol. 2018;19(1):16. doi:10.1186/s13059-018-1388-2
   Web of Science ®Google Scholar
• Boegel S, et al. In silico HLA typing using standard RNA-Seq sequence reads. In: Bugert P, editor. Molecular Typing of Blood Cell Antigens. New York: Springer New York; 2015:247–258.
   Google Scholar
• McCarthy DJ, Humburg P, Kanapin A, et al. Choice of transcripts and software has a large effect on variant annotation. Genome Med. 2014;6(3):26. doi:10.1186/gm543
   Web of Science ®Google Scholar
• Jarvik GP, Browning BL. Consideration of cosegregation in the pathogenicity classification of genomic variants. Am J Human Genetics. 2016;98(6):1077–1081. doi:10.1016/j.ajhg.2016.04.003
   Web of Science ®Google Scholar
• Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics Med. 2015;17(5):405–424. doi:10.1038/gim.2015.30
   PubMed Web of Science ®Google Scholar
• Gaedigk A, Sangkuhl K, Whirl-Carrillo M, et al. Prediction of CYP2D6 phenotype from genotype across world populations. Genetics Med. 2017;19(1):69–76. doi:10.1038/gim.2016.80
   PubMed Web of Science ®Google Scholar
• Kim E-Y, Shin S-G, Shin J-G. Prediction and visualization of CYP2D6 genotype-based phenotype using clustering algorithms. Transl Clin Pharmacol. 2017;25(3):147–152. doi:10.12793/tcp.2017.25.3.147
   Google Scholar
• McInnes G, et al. Transfer Learning Enables Prediction of CYP2D6 Haplotype Function. bioRxiv; 2020:684357.
   Google Scholar
• van der Lee M, Allard WG, Bollen S, et al. Repurposing of diagnostic whole exome sequencing data of 1583 individuals for clinical pharmacogenetics. Clin Pharmacol Ther. 2020;107(3):617–627. doi:10.1002/cpt.1665
   Web of Science ®Google Scholar
• Srinivasan BS, Chen J, Cheng C, et al. Methods for analysis in pharmacogenomics: lessons from the Pharmacogenetics Research Network Analysis Group. Pharmacogenomics. 2009;10(2):243–251. doi:10.2217/14622416.10.2.243
   Web of Science ®Google Scholar